STUDY PROTOCOL
Published on 07 Jan 2025
The combination treatment of RC48 and STAT3 inhibitor acts as a promising therapeutic strategy for basal bladder cancer
doi 10.3389/fimmu.2024.1432586
- 571 views
- Frontiers in Oncology
- Genitourinary Oncology
- Research Topics
- Antibody-Drug Conjugate Use in GU Malignancies
Antibody-Drug Conjugate Use in GU Malignancies
3,472
Total downloads
10k
Total views and downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Articles
CASE REPORT
Published on 29 Nov 2024
Case report: Two cases of leptomeningeal metastases in patients with metastatic urothelial carcinoma treated with enfortumab vedotin
doi 10.3389/fonc.2024.1434814
- 490 views
CASE REPORT
Published on 26 Jun 2024
Case report: Disitamab vedotin combined with immunotherapy demonstrated excellent efficacy in scrotal Paget’s disease with Her-2 overexpression
doi 10.3389/fimmu.2024.1349033
- 1,534 views
- 1 citation
SYSTEMATIC REVIEW
Published on 12 Jun 2024
Efficacy and safety of antibody–drug conjugates in the treatment of urothelial cell carcinoma: a systematic review and meta-analysis of prospective clinical trials
doi 10.3389/fphar.2024.1377924
- 1,164 views
- 1 citation
ORIGINAL RESEARCH
Published on 12 Jun 2024
Enfortumab vedotin–related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience
doi 10.3389/fonc.2024.1377842
- 1,751 views
- 2 citations
REVIEW
Published on 14 Mar 2024
Antibody–drug conjugates in urothelial carcinoma: scientometric analysis and clinical trials analysis
doi 10.3389/fonc.2024.1323366
- 2,031 views
- 1 citation
Published in
Frontiers in Oncology
- Genitourinary Oncology
- Pharmacology of Anti-Cancer Drugs
Participating Journals
Frontiers in Pharmacology
- 4.4 impact factor
- 7.8 citescore
Impact
- 10kTopic views
- 6,523Article views
- 3,472Article downloads